ICA Group Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

ICA Group Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.27K	Sell	42 -30	-42%	-$1.74K	﹤0.01%	674
2024 Q1	$4.91K	Hold	72	–	–	﹤0.01%	1039
2023 Q4	$4.51K	Buy	+72	New	+$3.98K	﹤0.01%	1048
2023 Q3	–	Sell	-30	Closed	-$1.68K	–	422
2023 Q2	$1.68K	Hold	30	–	–	﹤0.01%	1144
2023 Q1	$1.36K	Hold	30	–	–	﹤0.01%	1128
2022 Q4	$1.22K	Buy	+30	New	+$1.59K	﹤0.01%	1162

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ICA Group Wealth Management's CRSP Position: Q2 2024 in Review

ICA Group Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 42% in Q2 2024, selling an estimated $1.74K and leaving 42 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #674.

ICA Group Wealth Management first reported a position in CRSP in Q4 2022 and has held it in 6 quarters since. The position peaked at $4.91K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

ICA Group Wealth Management held 42 shares of CRISPR Therapeutics worth $2.27K as of Q2 2024.
ICA Group Wealth Management sold 30 CRISPR Therapeutics shares in Q2 2024, an estimated $1.74K.
CRISPR Therapeutics made up ﹤0.01% of ICA Group Wealth Management's portfolio in Q2 2024, its #674 holding.
ICA Group Wealth Management first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 6 quarters since.
ICA Group Wealth Management's CRISPR Therapeutics position peaked at $4.91K in Q1 2024.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.